Imlifidase Study Shows Potential for Kidney Transplants
The enzyme treatment enables successful transplants in sensitized patients by temporarily inactivating key antibodies.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Are you confident in the safety and efficacy of new medical treatments for transplant patients?
Hansa Biopharma recently presented the results of its PAES study, which examined 50 crossmatch-positive kidney transplants performed in Europe using the enzyme Imlifidase. The treatment, which received conditional marketing authorization in the EU in 2020, is currently under review by the FDA with a decision expected later this year.
Why it matters
Highly sensitized patients often face significant barriers to kidney transplantation due to pre-formed antibodies that cause graft loss, a problem affecting a subset of the 170,000 people currently on transplant waiting lists. Success in this study trajectory could expand the pool of eligible donors for these patients.
The study measured the efficacy of Imlifidase, an antibody-cleaving enzyme derived from Streptococcus pyogenes, in 50 kidney transplant cases. This represents the application of the therapy following its established conditional approval in the European Union.
The players
Hansa Biopharma
A Swedish biopharmaceutical company focused on developing immunomodulatory enzyme therapies for rare diseases and transplantation.
SERB Pharmaceuticals
A specialty pharmaceutical company that manages the European rights for Idefirix following a licensing agreement with Hansa Biopharma.
The details
Imlifidase works by inactivating IgG-antibodies, the proteins that identify foreign tissues and cause rejection, within hours of administration. By clearing these antibodies, the enzyme creates a temporary, antibody-free window that allows for transplantation in crossmatch-positive patients who would otherwise be incompatible with a donor organ. This process addresses the primary barrier for the estimated 10-15% of highly sensitized patients currently on transplant waitlists.
Timeline
August 25, 2020: Imlifidase received conditional marketing authorization in the EU.
February 2026: The FDA accepted the Biologics License Application for the enzyme.
July 1, 2026: The licensing agreement with SERB Pharmaceuticals became effective.
October 20, 2026: Hansa Biopharma announced the upcoming study presentation.
December 19, 2026: The FDA is scheduled to reach a PDUFA action decision.
The Tech Race
This presentation at ASN Kidney Week follows the established pattern of clinical data dissemination by manufacturers in the nephrology field. It places Hansa Biopharma’s platform into the broader competitive race to address long-standing immunological barriers to organ transplantation.
The therapy is currently available in the European Union and is pending regulatory review for the U.S. market. If approved, it would provide clinicians with a new tool to manage highly sensitized patients who are currently excluded from standard transplantation protocols.
The takeaway
This study underscores the potential for antibody-cleaving enzymes to alter the standard of care for sensitized transplant recipients. Stakeholders should track the FDA PDUFA action date set for December 19, 2026, which will determine the availability of this therapy for U.S. patients.
What happens next
The FDA is scheduled to announce its decision on the Biologics License Application for Imlifidase on December 19, 2026.
Further reading
For additional context on the latest developments in medical research, visit the /tech/biotech/.
More information
View the EU Idefirix product information for technical details on the therapy.
Live Poll
Are you confident in the safety and efficacy of new medical treatments for transplant patients?
